

VT/VF During Primary PCI



Bulent Gorenek MD FACC FESC

Eskişehir Osmangazi University
Cardiology Department
Eskişehir-Turkey

A variety of arrhythmias and conduction disturbances may occur; as sign of reperfusion, as complication of the intervention or as complication of acute MI in patients undergoing primary PCI

Serious ventricular arrhythmias have been reported up to occur in 5% of the patients undergoing PCI, and in 30% of the patients undergoing primary PCI

Sustained VT and VF, Risk Factors and Predictors

Role of contrast agents

The risk of ventricular arrhythmias from intracoronary dye is greater with the injection of ionic (high osmolar) contrast agents into the right coronary artery, particularly in the setting of prolonged injection or a damped pressure tracing

VF may occur if dye is allowed to remain static in the coronary tree



Independent Predictors of Sustained Ventricular Arrhythmias

Predictor Variable	OR	p-Value	95% CI
Use of low-osmolar ionic agents vs			
→ Nonionic agents	2.6	0.02	1.1–5.9
High-osmolar ionic agents	5.1	0.01	1.5–17.9
History of ventricular arrhythmias	7.8	<0.001	3.9–15.8
Angiography within 24 hr of AMI	3.5	0.001	1.6–7.6

CI = confidence interval.

Nonionic agents in diagnostic coronary angiography may be associated with an increased risk of sustained ventricular arrhythmias

Nonionic contrast agents should be preferred during acute MI, especially in high risk patients to decrease the risk of serious ventricular arrhythmias



VF may occur with guide catheter wedging or prolonged balloon inflations

Presence of Heart Failure

TABLE 4 Outcomes of Percutaneous Intervention by Killip Class

	Class I (n = 2,305)	Class II (n = 302)	Class III (n = 47)	p Value
PCI attempted (%)	89	88	82	NS
Success (%)*	97	95	96	NS
TIMI 3 flow (%)	93	90	94	NS
Final stenosis (%)	15 ± 17	18 ± 20	15 ± 20	NS
No. of stents [†]	1.4 ± 0.7	1.6 ± 0.8	1.4 ± 0.7	NS
Peak CK	2,012 ± 1,975	2,579 ± 2,719	2,913 ± 2,634	0.0001
IABP (%) [‡]	3	13	36	0.001
Renal failure [§] (%)	1	2	33	<0.001
Arrhythmia (%)	6	13	13	0.001
Major bleed [¶] (%)	8	12	24	0.001
Length of stay (d)	6.2 ± 5.3	8.2 ± 78.0	10.8 ± 11.5	0.0001
In-hospital (%)				
Stroke	0.6	0.8	2	NS
Reinfarction	1	4	5	0.001
CABG	4	6	6	NS
Death (%)				
In-hospital	2.4	7.0	19.2	0.001
6 mo	4.0	10	28	0.001

*Success defined as <50% residual stenosis and more than or equal to TIMI 2 flow.

[†]A total of 680 patients received stents.

[‡]Does not include PAMI 2 patients randomized to prophylactic IABP insertion.

[§]Requiring transient or permanent dialysis.

^{||}Brady- or tachycardia requiring pharmacologic therapy or temporary/permanent pacemaker insertion.

[¶]Requiring blood transfusion.

CK = creatinine kinase; IABP = intra-aortic balloon pulsation; other abbreviations as in Table 1.

Killip classification predicts the incidence of arrhythmias in patients undergoing PCI for acute MI

Importance of Vessel Diameter

Baseline characteristics and electrophysiological data of study patients			
	Gr I (Vf)-RCA	Gr II (RCA)	P value
Number	16	51	
Sex (M/F)	15/1	48/3	
Age (years)	71±8	70±9	0.38
MI	5/16 (31.2%)	15/51 (29.4%)	0.26
CAD	1.8±0.7	1.9±0.8	0.5
RCA total occlusion	5/16	14/51	0.14
Coronary risk factors			
Smoking	11/16 (68.7%)	29/51 (56.8%)	0.51
Hypertension	9/16 (56.2%)	31/51 (60.7%)	0.42
DM	8/16 (50.0%)	20/51 (39.2%)	0.09
Hyperlipidemia	6/16 (37.5%)	14/51 (27.4%)	0.06
LVEF (%)	40.5±5.9	41.2±7.4	0.09
RCA-0 (mm)	2.7±0.8	4.1±1.2	<0.001
LCA-0 (mm)	5.2±1.2	5.4±1.6	0.18
QT dispersion (ms)	66.3±20.5	69.3±17.5	0.24
ST change	11/16 (68.7%)	5/51 (9.8%)	0.01
BUN (mg/dl)	19.8±9.1	22.4±14.9	0.26
Cr (mg/dl)	1.1±0.4	1.3±0.7	0.3
Na (mmol/l)	140.4±2.9	140.1±2.2	0.6
K (mmol/l)	4.2±0.6	4.3±0.3	0.7
ASA	16/16 (100%)	50/51 (98%)	0.6
Nitrate	16/16 (100%)	48/51 (94.1%)	0.5
Ca-antagonist	6/16 (37.5%)	15/51 (29.4%)	0.11
ACEI	11/16 (68.7%)	27/51 (52.3%)	0.24

In patients with small caliber of RCA associated ST segment changes, the risk of VF was higher during PCI

QT Dispersion





FIGURE 1. QT_c dispersion in patients with (closed circle) and without (open circle) lethal ventricular arrhythmias complicating angioplasty before angioplasty.

Increased QT_c dispersion may predict the risk for lethal ventricular arrhythmias during PCI

The fact that successful angioplasty decreased QT_c dispersion indicates that a part of increased QT_c dispersion is related to myocardial ischemia in patients with coronary artery disease


Late Potentials in SAECG & PCI

Figure 2. Bar graph showing the prevalence of late potentials according to the reperfusion method. PTCA = percutaneous transluminal coronary angioplasty.



Primary PCI reduces the prevalence of LP more than thrombolytic agents do. The reduction is more pronounced in rescue PCI

Infarct Location


	Ventricular fibrillation		<i>p</i> -Value
	Before PCI	During PCI	
	(<i>n</i> =145) (5%)	(<i>n</i> =74) (3%)	
Male (%)	120 (83)	52 (70)	0.03
Age >60 years	65 (45)	44 (59)	0.04
Anterior infarction (%) 	96 (66)	29 (39)	<0.001
Previous coronary event (%)	19 (13)	13 (18)	0.38
Family history (%)	57 (39)	25 (34)	0.42
Hypertension (%)	29 (20)	18 (24)	0.46
Diabetes (%)	10 (7)	9 (12)	0.19
Hypercholesterolaemia (%)	25 (17)	10 (13)	0.48
Smoking (%)	71 (49)	37 (50)	0.88
Killip >1(%)	35 (24)	9 (12)	0.04
Preinfarction angina (%) ^a	32 (27)	28 (47)	0.009

Characteristics of the patients who had VF before PCI and during PCI

Infarct location was a major determinant of timing of VF, anterior infarction had greater risk for VF before PCI

TIMI Flow and ST Resolution

Figure 1. Postprocedural TIMI Flow and ST Resolution and Incidence of Late VT/VF



TIMI indicates thrombolysis in myocardial infarction; VT/VF, ventricular tachycardia or fibrillation. Error bars indicate 95% CIs.

Infarct Size



EUROPEAN
SOCIETY OF
CARDIOLOGY®

European Heart Journal (2009) 30, 757–764

doi:10.1093/eurheartj/ehp005

CLINICAL RESEARCH

Coronary heart disease

Reperfusion ventricular arrhythmia ‘bursts’ predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction

Mohamed Majidi^{1,2}, Andrzej S. Kosinski^{1,3}, Sana M. Al-Khatib^{1,4}, Miguel E. Lemmert², Lilian Smolders², Anton van Weert⁵, Johan H.C. Reiber^{5,6}, Dan Tzivoni⁷, Frits W.H.M. Bär², Hein J.J. Wellens⁸, Anton P.M. Gorgels^{2,8}, and Mitchell W. Krucoff^{1,4*}




Figure 3 Box plot presenting the correlation of presence or absence of reperfusion ventricular arrhythmia bursts ('BURST' vs. 'no BURST') with Day 7/discharge myocardial infarct size as measured by single-photon emission computed tomography.

Hypertension&Diabetes Mellitus

Variable	VF		p Value
	No (n = 19,333)	Yes (n = 164)	
Men	13,110 (68%)	101 (62%)	0.08
Age (yrs)			
<65	9,326 (48%)	66 (40%)	0.11
65–75	6,395 (33%)	61 (37%)	
>75	3,562 (19%)	37 (23%)	
Creatinine >1.5 mg/dl	1477 (8%)	3 (2%)	0.002
Previous myocardial infarct	6,979 (36%)	55 (34%)	0.50
Previous coronary bypass	4,294 (22%)	20 (12%)	0.002
Diabetes mellitus ←	5,362 (28%)	24 (15%)	<0.001
Ejection fraction <40%	2,127 (15%)	19 (12%)	0.18
Hypertension ←	8,277 (43%)	124 (76%)	<0.001
Ionic contrast	11,555 (60%)	109 (66%)	0.08

Patients developing VF during PCI were more likely to have a history of hypertension and DM


Independent Risk Predictors

Table 4. Adjusted Odds Ratios of Clinical Variables Associated With the Risk of Ventricular Tachycardia or Fibrillation During Primary Percutaneous Coronary Intervention

Outcome	Odds Ratio	95% Confidence Interval	p Value
Current smoker	1.95	1.26–3.02	0.0027
No beta-blocker in the ER	2.34	1.35–4.07	0.0026
RCA as infarct artery	1.93	1.25–2.99	0.0033
Time from symptom onset to ER \leq 180 min	2.63	1.42–4.89	0.0022
Initial TIMI flow grade 0	2.06	1.23–3.47	0.0062


Smoking, lack of beta blocker administration in ER, RCA as IRA, presence of initial TIMI grade 0 flow and timing of PCI were the independent risks for VT/VF during PCI

Time from symptom onset to ER arrival and frequency of VT/VF




The frequency of VT/VF increases as the time from symptom onset to ER arrival decreases

Increasing number of risk factors and the incidence of VT/VF



The frequency of VT/VF increases as the number of risk predictors increases

Incidence of VT/VF in Various Risk Categories



The incidence of VT/VF and mortality increased as patients' baseline risk increased

Prophylactic Strategies

Adenosine has been shown to suppress reperfusion injury and to terminate VT caused by intracellular calcium overload


Lerman BB, et al. Circulation, 1993

Arrhythmia Type	DP(n=23)	Non-DP(n=38)	p
PVC \geq 1 bpm	9(39.1%)	14(36.8%)	0.86
AIVR/VT	0	7/3(26.3%)	<0.01
VF	0	2(5.3%)	0.52

Administration of dipyridamole, increasing interstitial myocardial concentration of adenosine, can prevent and terminate reperfusion arrhythmias such as AIVR and VT in patients undergoing primary PCI

Yoshida et al, Circulation, 2000

RAS inhibition may decrease reperfusion arrhythmias



Intra-coronary enalaprilat infusion in the infarct related artery is feasible in the setting of primary angioplasty which is safe and well tolerated

Effective cardiac ACE inhibition can be achieved by low-dose intracoronary enalaprilat, which primarily causes a potentiation of bradykinin

TABLE 3. EFFECTS OF PRETREATMENT WITH LOSARTAN ON THE NUMBER OF VENTRICULAR PREMATURE CONTRACTIONS (VPC) AND VENTRICULAR TACHYCARDIA (VT) AND THE TOTAL DURATION OF VENTRICULAR FIBRILLATION (VF) WHICH OCCURRED DURING 45 MIN LEFT CORONARY ARTERY OCCLUSION PERIOD IN ANAESTHETIZED SHR

Group	N	VPC (no.)	VT (no.)	VF (sec)
Control	10	104.3 ± 27.0	7.7 ± 3.4	165.0 ± 27.5
Losartan, 2 mg/kg	8	105.8 ± 37.4	4.0 ± 2.0	18.0 ± 12.0*
Losartan, 5 mg/kg	8	46.5 ± 10.2*	7.0 ± 5.0	55.0 ± 15.0*
Losartan, 10 mg/kg	10	73.8 ± 12.0	2.5 ± 1.0	107.8 ± 71.0

N represents the number of rats. Values are expressed as means ± SEM.

*P < .05 v control value.

Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in hypertensive rats




Figure 2. Adjusted ORs for intraprocedural VT or VF requiring cardioversion in patients receiving preprocedural BBs versus none in acute myocardial infarction, by subgroup.

Pre-PCI beta blocker use was associated with decreased arrhythmia and mortality, without increasing rates of cardiogenic shock and heart failure


Antiarrhythmic Effect of Repeated Coronary Occlusion During Balloon Angioplasty

RR interval
(ms)

Blood pressure
(mmHg)

RR interval
(ms)

Blood pressure
(mmHg)



First occlusion

Second occlusion

A preceding, short vessel occlusion-reperfusion cycle seems to increase the electrical stability of ischemic myocardium

	IABC	No IABC or IABC	All Patients	p
	Pre intervention	Post intervention		
Cardiogenic shock (n=119)	12.9%	29.8%	21.0%	0.02
CHF or low EF(≤30%) (n=119)	0%	5.8%	5.0%	0.32
All high risk patient (n=238)	10.3%	14.4%	13.0%	0.38

In high risk patients prophylactic use of IABC may decrease the incidence of VF, especially in patients with cardiogenic shock

Management


Ventricular arrhythmias usually terminate without any intervention

Sustained VT associated with hemodynamic compromise, or VF should be treated with synchronized electrical cardioversion/defibrillation

No drug therapy is recommended, unless arrhythmias remain after PCI


Outcomes of VT/VF

Figure 2. Ninety-Day Mortality



No. at risk	0	10	20	30	40	50	60	70	80	90
Late VT/VF	117	91	81	80	80	80	80	80	78	76
Early VT/VF	203	177	173	168	168	168	168	168	168	163
No VT/VF	5405	5307	5264	5254	5245	5231	5224	5219	5212	5119


During the 90-day period, the total numbers of deaths were 39 for the late VT/VF category, 35 for early VT/VF, and 195 for no VT/VF. Log-rank $P < .001$ for comparisons between no VT/VF and early VT/VF, no VT/VF and late VT/VF, and early VT/VF and late VT/VF. VT/VF indicates ventricular tachycardia or fibrillation.



Number at risk:

VT/VF	181	174	172	168	164	163	161	156	156	92
no VT/VF	3304	3089	3060	3030	2971	2955	2920	2857	2834	1960

A



Number at risk:

VT/VF	181	166	161	156	148	147	144	138	130	80
no VT/VF	3304	2950	2862	2789	2616	2570	2516	2434	2395	1650

B

Sustained VT/VF after PCI in the HORIZONS-AMI trial was not significantly associated with 3-year mortality or major adverse clinical events

Figure 2. Time-to-event curves for 3-year mortality (A) and major adverse clinical events (B) in patients with versus without post procedural ventricular tachycardia or ventricular fibrillation.

Conclusions

Arrhythmias may occur either as complication of intervention or as complication of acute MI in patients undergoing primary PCI

However, in many cases VT/VF are the predictors of successful reperfusion

Generally, they tend to revert spontaneously, but when necessary, electrical cardioversion/defibrillation should be applied promptly

VT/VF during primary PCI do not influence PCI success. The extremely short time to defibrillation and easy access to other emergency equipment likely explain this

Long term outcomes are not affected by these arrhythmias



Maiden Tower, Istanbul-TURKEY